(Q34164822)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

15

Koji Arihiro

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

16

Kazuaki Chayama

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

10

Michio Imamura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

2

Masataka Tsuge

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

11

Shoichi Takahashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

14

Shinji Tanaka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

12

Hidenori Ochi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

13

C Nelson Hayes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

6

Hideyuki Hyogo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

9

Nobuhiko Hiraga

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1

Mayu Ohnishi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

Tomohiko Kohno

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Yizhou Zhang

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Hiromi Abe

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Yuki Kimura

series ordinal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

18 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

834-844

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350701%20AND%20SRC:MED&resulttype=core&format=json

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Analysis of a successful immune response against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

E2 of hepatitis C virus inhibits apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 Allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

The natural course of chronic hepatitis C: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Verification of the addiction severity index Japanese version (ASI-J) as a treatment-customization, prediction, and comparison tool for alcohol-dependent individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Decrease in the prevalence of adolescent alcohol use and its possible causes in Japan: periodical nationwide cross-sectional surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0550-Y

Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C

21 January 2018

1 reference

12 December 2020

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

12 December 2020

I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology

1 reference

12 December 2020

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

12 December 2020